NCT04940156

Brief Summary

The aim of this project is to study the performance of the two most commonly used Implantable Cardiac Monitors in detecting AF episodes and explore how the new connectivity can empower patients and improve patient care.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable atrial-fibrillation

Timeline
Completed

Started Oct 2021

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 17, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 25, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

October 4, 2021

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 23, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 23, 2023

Completed
11 months until next milestone

Results Posted

Study results publicly available

October 15, 2024

Completed
Last Updated

October 15, 2024

Status Verified

July 1, 2024

Enrollment Period

2.1 years

First QC Date

June 17, 2021

Results QC Date

June 19, 2024

Last Update Submit

July 22, 2024

Conditions

Keywords

Confirm RxReveal LINQ

Outcome Measures

Primary Outcomes (1)

  • Assessment of Performance of Confirm Rx ICM and Reveal LINQ ICM in Detecting AF Episodes in Comparison to CIED

    To assess the performance of the Confirm Rx™ ICM and Reveal LINQ™ ICM in detecting clinically significant AF episodes (episodes longer than 6 minutes) in comparison to CIED (gold standard). Confirm Rx and Reveal LINQ™ ICM sensitivity, specificity, positive predictive value and negative predictive value will be calculated for AF episodes longer than 6 minutes.

    During follow-up (6 months)

Secondary Outcomes (3)

  • Comparison of Changes in R-wave Amplitude Following Implantation in Both ICMs.

    During follow-up (6 months)

  • To Compare the Transmission Success Rate of Both Devices.

    During follow-up (6 months)

  • To Compare the Number of Patient-activated Recordings That Contains Symptoms.

    During follow-up (6 months)

Study Arms (2)

Patients implanted with the Abbott Confirm Rx ICM

OTHER

Patient with cardiac implantable electronic devices with an atrial lead will have Confirm Rx Implantable Cardiac Monitor injected in the anterior chest wall.

Device: Confirm Rx (Implantable Cardiac Monitor)

Patients implanted with the Medtronic LINQ ICM

OTHER

Patient with cardiac implantable electronic devices with an atrial lead will have LINQ Implantable Cardiac Monitor injected in the anterior chest wall.

Device: Reveal LINQ (Implantable Cardiac Monitor)

Interventions

Confirm Rx implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)

Patients implanted with the Abbott Confirm Rx ICM

Reveal LINQ implanted in patients with atrial fibrillation detected on their cardiac implantable electronic device (CIED)

Patients implanted with the Medtronic LINQ ICM

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participant is willing and able to give informed consent for participation in the trial.
  • Male or Female.
  • Aged 18 years or above.
  • History of paroxysmal and persistent AF.
  • Dual-chamber pacemaker, Implantable cardioverter defibrillator (ICD) or cardiac resynchronisation therapy (CRT) device with a functioning atrial lead, able to record electrograms and remote monitoring.

You may not qualify if:

  • Diagnosis of permanent AF.
  • Contra-indications for implantable cardiac monitor.
  • Unable to comply with the follow-up schedule.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

John Radcliffe Hospital

Oxford, United Kingdom

Location

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Dr Richard Varini
Organization
Oxford University Hospitals NHS Trust

Study Officials

  • Tim Betts, MD FRCP

    Oxford University Hospitals NHS Trust

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Primary Investigator

Study Record Dates

First Submitted

June 17, 2021

First Posted

June 25, 2021

Study Start

October 4, 2021

Primary Completion

November 23, 2023

Study Completion

November 23, 2023

Last Updated

October 15, 2024

Results First Posted

October 15, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share

Locations